The outlook of companies tied to the drug's legacy presents a complex investment landscape. While the initial boom generated substantial gains, generic alternatives have significantly eroded market share . https://yxzbookmarks.com/story21634430/copyright-s-flagship-product-and-pharma-a-uncertain-opportunity